BCMA CAR / Vaxcell-Bio Therap - LARVOL DELTA

Anti-B-Cell Maturation Antigen Dual-Epitope Chimeric Antigen Receptor Marrow-Infiltrating Lymphocytes for Multiple Myeloma (IMS 2026) - "Dual-epitope BCMA CAR-MILs combine BCMA-specific CAR activity with the memory-rich and tumor-reactive properties of marrow-derived T cells. This strategy may improve persistence, broaden antitumor recognition, and reduce vulnerability to antigen escape, supporting further clinical-enabling development toward first-in-human investigation."

First-in-human • Hematological Malignancies • Multiple Myeloma • CD8 • SDC1

Anti-BCMA Dual Epitope-Binding CAR-Marrow Infiltrating Lymphocytes (MILs) Could Offer a Potent Innovative Immunotherapeutic Tool Against Multiple Myeloma (ASH 2023) - "This study suggested that BCMA dual epitope-binding CAR-MILs were easily expanded and activated using bone marrow mononuclear cells from MM patients with high transduction efficiency and induced a potent anti-myeloma immune response, which may offer an alternative innovative immunotherapeutic approach against MM patients in the future."

Hematological Malignancies • Multiple Myeloma • Oncology • CD4 • CD73 • CD8 • HAVCR2 • IL15 • IL2 • IL21 • IL7 • LAMP1 • SDC1 • TIGIT

Anti-BCMA Dual Epitope-Binding CAR-Marrow Infiltrating Lymphocytes (MILs) against Multiple Myeloma (ICBMT 2024) - "Additionally, in vivo study clearly showed that BCMA CAR MILs more effectively inhibited RPMI8226 tumor growth and greatly prolonged the survival of vaccinated mice. Conclusions : Based on the promising preclinical data, BCMA CAR MIL will be explored in a first-in-human phase I study in Korea to assess the safety, pharmacokinetics, immunogenicity, efficacy, and duration of effect for patients with relapsed or refractory multiple myeloma."

Hematological Malignancies • Multiple Myeloma • Oncology • CD8 • IL15 • IL2 • IL21 • IL7 • SDC1

Vaxcell Bio forms a scientific advisory group and launches an integrated R&D center [Google translation] (HIT News) - "Vaxcell Bio signed a one-year advisory contract with new scientific advisory committee members, including Dr. Byeong-wook Ryu, who has led the research and development of CAR-T treatments in the United States, and Professor Seung-hwan Lee, a professor at the University of Ottawa in Canada, who is considered an authority on immune cell therapy research and development...'With the joining of the two scientists, the research and development of CAR-T, CAR-NK, and CAR-MILs, the Vax-CAR platform built by Vaxcell Bio, will accelerate and will have the effect of being recognized externally.'....Vaxcell Bio believes that the integration of the R&D organization will accelerate the speed of research and development throughout the entire process from basic research to preclinical and clinical trials and increase work efficiency."

Licensing / partnership • Gastrointestinal Cancer • Hematological Malignancies • Lung Cancer • Multiple Myeloma • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Small Cell Lung Cancer • Solid Tumor